BridgeBio Pharma (NASDAQ: BBIO) shareholder schedules August stock sale

Rhea-AI Filing Summary

BridgeBio Pharma Inc. (symbol BBIO) reports a planned sale of 21,501 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $1,717,069.86, expected on August 17, 2026 on NASDAQ. The shares are to be sold in connection with an exercise of stock options, with the issuer listed as the party receiving cash for the option exercise.

During the prior three months, Randal Scott reported 10b5-1 plan sales of 2,196 shares of common stock on June 24, 2026 for total proceeds of $152,073.00.

Key Figures

Planned shares to be sold: 21,501 shares Aggregate market value of planned sale: $1,717,069.86 Planned sale date: 08/17/2026 +2 more

5 metrics

Planned shares to be sold 21,501 shares Common stock covered by the Form 144 sale notice

Aggregate market value of planned sale $1,717,069.86 Market value of 21,501 BBIO shares to be sold

Planned sale date 08/17/2026 Intended sale date for the 21,501 BBIO shares on NASDAQ

Shares sold in past 3 months 2,196 shares 10b5-1 plan sale on 06/24/2026 for Randal Scott

Proceeds from past 3 months sale $152,073.00 Total proceeds from 2,196 BBIO shares sold on 06/24/2026

Key Terms

Form 144, Exercise of Stock Options, 10b5-1, Executive Financial Services

4 terms

Form 144 regulatory

"144: Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Exercise of Stock Options financial

"Common | 08/17/2026 | Exercise of Stock Options | Issuer"

10b5-1 regulatory

"10b5-1 Sales for RANDAL SCOTT 3160 PORTER DRIVE"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

What is BridgeBio Pharma (BBIO) reporting in this Form 144 filing?

BridgeBio Pharma (BBIO) reports a planned sale of 21,501 shares of common stock related to an exercise of stock options, with an aggregate market value of $1,717,069.86 and an expected sale date of August 17, 2026 on NASDAQ.

How many BBIO shares are planned to be sold and at what value?

The filing covers a planned sale of 21,501 shares of BBIO common stock with an aggregate market value of $1,717,069.86. These shares are associated with an exercise of stock options and are expected to be sold on August 17, 2026.

What recent 10b5-1 plan sales are disclosed for BBIO in this Form 144?

The filing notes that under a 10b5-1 plan, 2,196 shares of BBIO common stock were sold on June 24, 2026 for total proceeds of $152,073.00. These sales were for Randal Scott and occurred within the past three months.

Who is handling the planned BBIO share sale disclosed in the Form 144?

The planned sale of 21,501 BBIO shares is listed under Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as the broker facilitating the common stock transaction on NASDAQ.

What is the relationship between the BBIO option exercise and the Form 144 sale?

The 21,501 shares of BBIO common stock covered by this Form 144 are tied to an exercise of stock options, with the issuer designated to receive cash upon exercise. The shares obtained from this exercise are then planned for sale on August 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 04:33 PM Accepted by SEC EDGAR 08/17/2026 - 04:32 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	21501	1717069.86	195487474	08/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/17/2026	Exercise of Stock Options	Issuer			21501	08/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for RANDAL SCOTT 3160 PORTER DRIVE SUITE 250 Palo Alto CA 94304	Common	06/24/2026	2196	152073.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)